Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis

被引:3
作者
Ju, Xuan [1 ]
Jiang, Zhenliang [1 ]
Ma, Jiayin [1 ]
Yang, Dong [1 ]
机构
[1] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing Key Lab Funct Food Plant Resources, Beijing 100083, Peoples R China
关键词
irritable bowel syndrome; short-chain fatty acids; gut microbiota; low-FODMAP diet; FMT; IRRITABLE-BOWEL-SYNDROME; TRADITIONAL DIETARY ADVICE; GUT MICROBIOTA; INTESTINAL MICROBIOTA; ALTERED PROFILES; SYMPTOMS; FERMENTATION; METABOLITES; PATHWAYS; ORIGIN;
D O I
10.3390/nu16111727
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Context: Short-chain fatty acids (SCFAs) have been reported to be associated with the pathogenesis of irritable bowel syndrome (IBS), but the results are conflicting. Objective: Here, a systematic review of case-control studies detecting fecal SCFAs in IBS patients compared with healthy controls (HCs) and self-controlled studies or randomized controlled trials (RCTs) investigating fecal SCFA alterations after interventions were identified from several databases. Data sources: A systematic search of databases (PubMed, Web of Science, and Embase) identified 21 studies published before 24 February 2023. Data extractions: Three independent reviewers completed the relevant data extraction. Data analysis: It was found that the fecal propionate concentration in IBS patients was significantly higher than that in HCs, while the acetate proportion was significantly lower. Low-FODMAP diets significantly reduced the fecal propionate concentration in the IBS patients while fecal microbiota transplantation and probiotic administration did not significantly change the fecal propionate concentration or acetate proportion. Conclusions: The results suggested that the fecal propionate concentration and acetate proportion could be used as biomarkers for IBS diagnosis. A low-FODMAP diet intervention could potentially serve as a treatment for IBS while FMT and probiotic administration need more robust trials.
引用
收藏
页数:15
相关论文
共 82 条
[1]   Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome [J].
Acosta, Andres ;
Camilleri, Michael ;
Shin, Andrea ;
Nord, Sara Linker ;
O'Neill, Jessica ;
Gray, Amber V. ;
Lueke, Alan J. ;
Donato, Leslie J. ;
Burton, Duane D. ;
Szarka, Lawrence A. ;
Zinsmeister, Alan R. ;
Golden, Pamela L. ;
Fodor, Anthony .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2016, 7
[2]   A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome [J].
Ahluwalia, Bani ;
Iribarren, Cristina ;
Magnusson, Maria K. ;
Sundin, Johanna ;
Clevers, Egbert ;
Savolainen, Otto ;
Ross, Alastair B. ;
Tornblom, Hans ;
Simren, Magnus ;
Ohman, Lena .
CELLS, 2021, 10 (06)
[3]   Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation [J].
Akhtar, Muhammad ;
Chen, Yan ;
Ma, Ziyu ;
Zhang, Xiaolong ;
Shi, Deshi ;
Khan, Jawaria A. ;
Liu, Huazhen .
ANIMAL NUTRITION, 2022, 8 :350-360
[4]   Cytokines and irritable bowel syndrome: Where do we stand? [J].
Bashashati, Mohammad ;
Rezaei, Nima ;
Andrews, Christopher N. ;
Chen, Chun-Qiu ;
Daryani, Nasser Ebrahimi ;
Sharkey, Keith A. ;
Storr, Martin A. .
CYTOKINE, 2012, 57 (02) :201-209
[5]   Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome [J].
Carroll, I. M. ;
Ringel-Kulka, T. ;
Siddle, J. P. ;
Ringel, Y. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 24 (06) :521-+
[6]   Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome [J].
Carroll, Ian M. ;
Ringel-Kulka, Tamar ;
Keku, Temitope O. ;
Chang, Young-Hyo ;
Packey, Christopher D. ;
Sartor, R. Balfour ;
Ringel, Yehuda .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2011, 301 (05) :G799-G807
[7]   Irritable Bowel Syndrome A Clinical Review [J].
Chey, William D. ;
Kurlander, Jacob ;
Eswaran, Shanti .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (09) :949-958
[8]   A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome [J].
Codling, Caroline ;
O'Mahony, Liam ;
Shanahan, Fergus ;
Quigley, Eamonn M. M. ;
Marchesi, Julian R. .
DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (02) :392-397
[9]   Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial [J].
Cremon, Cesare ;
Guglielmetti, Simone ;
Gargari, Giorgio ;
Taverniti, Valentina ;
Castellazzi, Anna Maria ;
Valsecchi, Chiara ;
Tagliacarne, Carlotta ;
Fiore, Walter ;
Bellini, Massimo ;
Bertani, Lorenzo ;
Gambaccini, Dario ;
Cicala, Michele ;
Germana, Bastianello ;
Vecchi, Maurizio ;
Pagano, Isabella ;
Barbaro, Maria Raffaella ;
Bellacosa, Lara ;
Stanghellini, Vincenzo ;
Barbara, Giovanni .
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (04) :604-613
[10]   Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions [J].
Cumpston, Miranda ;
Li, Tianjing ;
Page, Matthew J. ;
Chandler, Jacqueline ;
Welch, Vivian A. ;
Higgins, Julian P. T. ;
Thomas, James .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10)